129 related articles for article (PubMed ID: 9203042)
1. In vitro drug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b.
Küpeli B; Baltaci S; Beksac M; Süzer O; Küpeli S; Göğüs O
Int Urol Nephrol; 1997; 29(1):79-84. PubMed ID: 9203042
[TBL] [Abstract][Full Text] [Related]
2. Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.
Küpeli S; Beksac M; Küpeli B; Baltaci S; Süzer O
Int Urol Nephrol; 1997; 29(4):421-6. PubMed ID: 9405998
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro.
Koch S; Mayer F; Honecker F; Schittenhelm M; Bokemeyer C
Br J Cancer; 2003 Dec; 89(11):2133-9. PubMed ID: 14647149
[TBL] [Abstract][Full Text] [Related]
4. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
5. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
6. In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a.
de Riese W; Allhoff E; Stief CG; Lenis G; Schlick R; Liedke S; Anton P; Jonas U
Urol Res; 1991; 19(2):87-90. PubMed ID: 1906658
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
8. Long-term complications of chemotherapy for germ cell tumours.
Chaudhary UB; Haldas JR
Drugs; 2003; 63(15):1565-77. PubMed ID: 12887263
[TBL] [Abstract][Full Text] [Related]
9. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
10. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.
Brennemann W; Stoffel-Wagner B; Helmers A; Mezger J; Jäger N; Klingmüller D
J Urol; 1997 Sep; 158(3 Pt 1):844-50. PubMed ID: 9258096
[TBL] [Abstract][Full Text] [Related]
11. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
[TBL] [Abstract][Full Text] [Related]
14. Bleomycin in germ cell tumor therapy: not all regimens are created equal.
Bajorin DF; Bosl GJ
J Clin Oncol; 1997 May; 15(5):1717-9. PubMed ID: 9164177
[No Abstract] [Full Text] [Related]
15. Role of metallothionein in cisplatin sensitivity of germ-cell tumours.
Meijer C; Timmer A; De Vries EG; Groten JP; Knol A; Zwart N; Dam WA; Sleijfer DT; Mulder NH
Int J Cancer; 2000 Mar; 85(6):777-81. PubMed ID: 10709094
[TBL] [Abstract][Full Text] [Related]
16. [Testicular malignant tumours. Efficacy of germ cell and sex cord tumours treatment protocol in Poland].
Popadiuk S; Korzon M; Chybicka A; Szmyd K; Dzierzega M; Trelińska J; Kowalczyk JR; Wiśniewska-Slusarz H; Woźniak W; Bilska K; Wachowiak J; Konatkowska B; Wysocki M; Krawczuk-Rybak M; Czauderna P; Szumera M; Sznurkowska K; Renke J
Med Wieku Rozwoj; 2006; 10(3 Pt 1):811-7. PubMed ID: 17317912
[TBL] [Abstract][Full Text] [Related]
17. Genetic basis of drug sensitivity in human testis tumour cells.
Wang X; Hafezparast M; Masters JR
Int J Cancer; 1996 Feb; 65(4):426-31. PubMed ID: 8621221
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer.
Dahl O; Vagstad G; Iversen B
Acta Oncol; 1996; 35(6):759-61. PubMed ID: 8938228
[No Abstract] [Full Text] [Related]
19. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours.
di Pietro A; Vries EG; Gietema JA; Spierings DC; de Jong S
Int J Biochem Cell Biol; 2005 Dec; 37(12):2437-56. PubMed ID: 16099193
[TBL] [Abstract][Full Text] [Related]
20. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
